International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

Pharmacovigilance: Safeguarding Drug Safety at Every Stage of Clinical Trials

Prof. (Dr.) Mohd. Wasiullah [1], Prof. (Dr.) Piyush Yadav [2], Asst. Prof.MohitVishwakarma[3*], Yadav Swati Chandraprakash [4]

Date of Submission: 20-04-2025 Date of Acceptance: 30-04-2025

ABSTRACT
Pharmacovigilance is a critical discipline in healthcare dedicated to ensuring the safety and efficacy of pharmaceutical products throughout their lifecycle—from preclinical studies to post-marketing surveillance. It involves the systematic detection, assessment, and prevention of adverse drug reactions (ADRs), playing a vital role in clinical trials (Phases I–IV) and beyond. Global regulatory bodies such as the WHO, ICH, FDA, and EMA provide frameworks that guide pharmacovigilance practices, promoting consistency and compliance. Advanced technologies like artificial intelligence, data mining, and pharmacovigilance software tools have enhanced the identification and management of safety signals. Despite challenges such as underreporting and data variability, continuous innovation and international collaboration are strengthening pharmacovigilance systems, ultimately safeguarding public health and reinforcing trust in healthcare and drug development.

KEYWORDS
Adverse Drug Reactions (ADRs), Pharmacovigilance Software,Signal Detection, Regulatory Compliance,Post-Marketing Surveillance, Artificial Intelligence in Drug Safety

I. INTRODUCTION

Pharmacovigilance is a specialized area within healthcare and the pharmaceutical domain, dedicated to the ongoing surveillance, evaluation, interpretation, and prevention of adverse drug reactions (ADRs) and other medication-related complications. The core purpose of pharmacovigilance is to guarantee the continued safety and therapeutic efficacy of medicinal products across all phases of their existence, from initial formulation and clinical evaluation to widespread clinical application and post-market follow-up. This expansive scope moves beyond the limits of clinical studies, embracing real-world data to safeguard public well-being.

[Preclinical Research]
↓
[Phase 1: Safety & Dosage]
↓
[Phase 2: Efficacy & Side Effects]
↓
[Phase 3: Large-Scale Confirmation]
↓
[Regulatory Approval]
↓
[Phase 4: Post-Market Monitoring]

FIG: FLOW CHART OF CLINICAL TRIAL

1.1 Definition of Pharmacovigilance

The term "pharmacovigilance" is derived from the Greek "pharmakon" (meaning drug) and the Latin "vigilare" (meaning to watch over), reflecting its essential function: to systematically observe and assess the effects of pharmaceutical agents to detect any harmful or unintended reactions. Although medications are formulated to manage, cure, or prevent illnesses, they may sometimes produce adverse effects, interact with other drugs, or result in long-term complications. The goal of pharmacovigilance is to maintain a favorable balance between a drug's therapeutic advantages and any associated risks

The World Health Organization (WHO) defines pharmacovigilance as “the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem.” This definition illustrates the dual nature of pharmacovigilance—combining empirical research and practical applications—to support patient safety. It includes structured collection and analysis of safety data from multiple sources, including clinical trials, healthcare practitioners, patients, and real-world use, in order to recognize trends or “signals” that may indicate emerging safety concerns.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

1.2 Significance of Pharmacovigilance

Pharmacovigilance is a critical pillar in maintaining the ongoing safety and reliability of therapeutic agents. Its importance can be articulated through the following dimensions: detecting adverse drug events (ADEs), ensuring patient well-being, compliance and risk governance, encouraging safe medication practices, and public health advancement.

1.3 Regulatory Framework in Clinical Trials

The regulatory landscape for pharmacovigilance within clinical trials encompasses an organized framework of protocols, laws, and quality standards established by international and regional authorities. These structures thrive on coordinated engagement between researchers, sponsors, regulatory agencies, healthcare providers, and trial subjects.

1.3.1 Global Regulatory Standards

The World Health Organization (WHO) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) are key international organizations that play a significant role in shaping and standardizing the safety monitoring of investigational drugs. The WHO's International Drug Monitoring Programme, initiated in 1968, aims to enhance global drug safety by collecting and analyzing data on adverse drug reactions (ADRs) from member countries. The ICH develops globally recognized standards for the safe conduct of clinical trials, including guidelines like ICH E2A Clinical Safety Data Management and ICH E2F Development Safety Update Report (DSUR).

1.3.2. Regional and National Regulatory Frameworks

Regional and national regulatory frameworks also play a role in pharmacovigilance. The European Union's Clinical Trials Regulation (CTR) 536/2014 governs the safe conduct of clinical trials within its member states, while the US Food and Drug Administration (FDA) oversees the safety of investigational drugs through the Code of Federal Regulations. In Japan, the Pharmaceuticals and Medical Devices Agency (PMDA) enforces regulations under the Pharmaceuticals and Medical Devices Act, and in India, the Central Drugs Standard Control Organization (CDSCO) monitors pharmacovigilance through the Drugs and Cosmetics Act and the New Drugs and Clinical Trials Rules (2019).

Core components of pharmacovigilance in clinical trials include adverse event reporting, safety data monitoring, risk management plans, development safety update reports, and suspected unexpected serious adverse reactions (SUSARs). Challenges in implementing regulatory frameworks include regulatory variability, underreporting, technological barriers, and ethical dilemmas. However, these organizations work together to ensure the safety and efficacy of investigational drugs in clinical trials.

2.Pharmacovigilance in Clinical Trials

Pharmacovigilance is a crucial aspect of clinical trials, ensuring drug safety and data reliability. It helps identify potential risks associated with investigational medications and maintains a balance between benefits and harms. Throughout the trials, from early testing in healthy volunteers to large-scale studies in patients, pharmacovigilance tracks and analyzes adverse events, detecting unexpected reactions and ensuring timely action. By adhering to strict regulatory guidelines and ethical standards, pharmacovigilance supports the development of safe and effective medicines.

2.1 Pre-clinical Trials

Pharmacovigilance is a crucial aspect of drug development, particularly during preclinical trials. These trials are conducted in laboratories and on animal models to assess the potential risks, side effects, and overall safety of new compounds. The primary objectives of preclinical trials include evaluating toxicity, determining safe doses, studying the drug's absorption, distribution, metabolism, and excretion, examining its mechanism of action, and identifying potential risks for genetic mutations, cancer, birth issues.

Pharmacovigilance plays a crucial role in preclinical trials by detecting safety signals from laboratory or animal data, assessing the severity, frequency, and potential impact of adverse effects, documenting observed toxicities, and adhering to ethical considerations. Types of preclinical safety studies include acute toxicity studies, sub-chronic and chronic toxicity, reproductive and developmental toxicity, genomictoxicity testing, and carcinogenicity studies.

Regulatory bodies provide strict guidelines for preclinical testing to ensure that potential medications are reasonably safe before

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

human trials. The International Council for Harmonisation (ICH) provides standards for biotechnology-based pharmaceuticals, while the Organization for Economic Co-operation and Development (OECD) sets GLP standards for consistent and reliable non-clinical studies. The U.S. Food and Drug Administration (FDA) requires detailed preclinical data for Investigational New Drug (IND) applications, and the European Medicines Agency (EMA) reviews preclinical safety data before approving human trials in Europe.

In conclusion, pharmacovigilance plays a vital role in preclinical trials, helping to predict potential risks and ensure the safety of new drugs before they are tested on humans.

2.2 Phase I-IV Clinical Trials

Pharmacovigilance is a crucial aspect of clinical trials, ensuring drug safety, assessing risk, and monitoring adverse drug reactions (ADRs) throughout the development process. It involves systematically analyzing safety data to minimize risks and enhance patient safety.

Phase I clinical trials involve assessing safety in humans, focusing on immediate, dose-related adverse effects, early safety signals, and establishing safe dosage ranges. Safety measures include close supervision of participants and prompt reporting of adverse events.

Phase II clinical trials focus on evaluating efficacy and safety in larger patients with the targeted condition, detecting potential side effects, refining dosages, monitoring patient responses, and analyzing adverse event data. Safety measures include structured adverse event reporting and frequent safety assessments to safeguard participants.

Phase III clinical trials confirm efficacy and safety by identifying less common and rare adverse effects due to a larger sample size, assessing drug interactions and demographic-specific responses, and preparing detailed safety data for regulatory approval. Safety measures include strict adherence to Good Clinical Practice standards and comprehensive monitoring for adverse events.

Phase IV clinical trials monitor long-term safety and effectiveness in the general population after a drug is approved and the market. Pharmacovigilance during this phase helps detect rare, long-term, or delayed adverse effects that may not have been identified during clinical trials.

Objectives of pharmacovigilance in post-marketing surveillance include detecting rare and delayed adverse effects, monitoring long-term safety, evaluating real-world effectiveness, identifying medication errors, managing risk, and updating safety profiles. Methods of post-marketing surveillance include spontaneous reporting systems, electronic health records, cohort and case-control studies, prescription event monitoring, active surveillance programs, and social media and digital health monitoring.

Regulatory bodies play a significant role in ensuring the effectiveness of pharmacovigilance in post-marketing surveillance, such as the FDA, EMA, WHO, and ICH. Challenges in post-marketing surveillance include underreporting of ADRs, data quality issues, global variability, and complex interpretation of data.

In conclusion, pharmacovigilance plays a vital role in clinical trials, ensuring drug safety, assessing risk, and monitoring adverse drug reactions (ADRs) throughout the development process.

3. Pharmacovigilance Activities and Tools Techniques

Pharmacovigilance is a crucial scientific and regulatory activity that aims to detect, assess, understand, and prevent adverse effects or drug-related problems, ensuring public health and the safety of medicinal products throughout their lifecycle. Key activities include adverse event reporting, serious adverse event reporting, signal detection and management, and risk management planning.

3.1Adverse Event Reporting

Adverse event (AE) refers to any unintended and harmful reaction experienced by a patient following the administration of a drug, regardless of whether it is related to the drug. Reporting is crucial for pharmacovigilance, allowing regulatory authorities and pharmaceutical companies to monitor drug safety post-marketing and take necessary actions to protect patients. Methods of reporting include spontaneous reporting, solicited reporting, and electronic reporting systems. Challenges in adverse event reporting include underreporting due to lack of awareness or time constraints, incomplete data, and complex causality assessment. Healthcare professionals and patients often fail to report adverse events due to lack of awareness or time constraints.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

3.2 Serious Adverse Event Reporting

A serious adverse event (SAE) is a serious medical condition resulting in death, life-threatening conditions, or hospitalization. It requires immediate attention and detailed reporting. Regulatory agencies like the FDA, EMA, and WHO mandate pharmaceutical companies report SAEs within 7 to 15 days for unexpected events and periodic safety update reports (PSURs) for marketed drugs. Healthcare professionals, including physicians, pharmacists, and nurses, play a crucial role in SAE reporting, documenting incident details to aid in regulatory decision-making.

3.3Pharmacovigilance Software

Pharmacovigilance software is a set of specialized applications that monitor, collect, analyze, and report adverse events (AEs) associated with pharmaceutical products. These tools are crucial for ensuring drug safety and regulatory compliance throughout a product's lifecycle. They facilitate the systematic collection and documentation of AE data, identify potential safety signals, evaluate risk severity and frequency, and ensure adherence to international safety reporting standards. Some notable pharmacovigilance software solutions include Oracle Argus Safety, ArisG, and ClinTrace, which offer robust automation and compliance features, case management, and reporting capabilities. These tools enable healthcare professionals to effectively manage drug safety data.

3.4 Data Mining and Analysis

Data mining is a crucial process in pharmacovigilance, involving the extraction of meaningful patterns from large datasets to uncover hidden associations between drugs and adverse events. Techniques like disproportionality analysis and Bayesian data mining are used to detect safety signals, such as those used by the FDA. Data mining also helps detect adverse drug reactions in electronic health records and healthcare databases, aiding regulatory agencies and pharmaceutical companies in monitoring drug safety and making informed risk management decisions.

4. Regulatory Requirements

Pharmacovigilance involves detecting, assessing, understanding, and preventing adverse effects or drug-related problems through regulatory guidelines established by international and national agencies. These guidelines ensure the safety and efficacy of medicinal products throughout their lifecycle.

4.1 International Council for Harmonisation (ICH) Guidelines

The International Council of Pharmaceutical Industry (ICH) creates guidelines to ensure safe, effective, and high-quality medicines are developed and registered efficiently across regions. Key guidelines include ICH E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, ICH E2E: Pharmacovigilance Planning, and ICH E2C(R2): Periodic Benefit-Risk Evaluation Report (PBRER). These guidelines aim to harmonize safety information gathering and reporting, provide guidance on planning pharmacovigilance activities, and outline the format and content of PBRERs, which evaluate the risk-benefit balance of a medicinal product at defined time points post-authorization.

4.2 U.S. Food and Drug Administration (FDA) Regulations

The FDA offers guidance to the pharmaceutical industry on good pharmacovigilance practices and pharmacoepidemiologic assessment of observational data. Key documents include Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment, which outlines recommendations for collecting and evaluating safety data, and E2E Pharmacovigilance Planning, aligned with the ICH E2E guideline, which aids in planning pharmacovigilance activities, particularly for the early post-marketing period of new drugs, focusing on safety signals and risk assessment methods.

4.3 European Medicines Agency (EMA) Guidelines

The European Medicines Agency (EMA) has introduced Good Pharmacovigilance Practices (GVP), a set of measures designed to improve pharmacovigilance in the EU. GVP applies to marketing authorization holders, the EMA, and medicines regulatory authorities in EU Member States. Module I focuses on the structure and processes of a pharmacovigilance system, emphasizing quality to ensure legal compliance and continuous improvement. Module VI details the requirements for managing and reporting suspected adverse reactions, including spontaneous reports, literature reports, and non-interventional studies.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

4.4 World Health Organization (WHO) Guidelines

The World Health Organization (WHO) is responsible for establishing global guidelines for pharmacovigilance, promoting international collaboration and standardization. These guidelines establish norms, technical support, and foster the development of pharmacovigilance systems worldwide. They ensure a harmonized approach to pharmacovigilance, safeguarding public health by monitoring and evaluating the safety profiles of medicinal products.

5. Challenges and Opportunities

Pharmacovigilance is crucial for drug safety during clinical trials and post-marketing, addressing challenges and leveraging opportunities to improve monitoring and patient outcomes.

5.1 Data Quality and Standardization

The growing volume and complexity of data from various sources complicates integration and analysis, while inconsistencies can lead to incomplete or inaccurate datasets. Opportunities include advanced data management systems that handle large volumes of diverse data and AI technologies that improve data quality by identifying errors, standardizing formats, and ensuring completeness and consistency in reporting.

5.2 Signal Detection and Validation

Data integration is a complex challenge, especially when dealing with diverse data sources like clinical trial data and spontaneous report databases. Timeliness is crucial, as delays can lead to patient exposure to risks. Opportunities lie in AI and Machine Learning, which can analyze large datasets to identify adverse drug reactions, and real-world data, which can provide insights into drug safety in diverse settings.

6. Best Practices

Adherence to best practices in pharmacovigilance, including proactive measures, risk-based approaches, collaboration, communication, and continuous monitoring and evaluation, is crucial for drug safety in clinical trials.

6.1 Proactive Pharmacovigilance

The best practices for drug safety include real-time data monitoring, predictive analytics, and active surveillance systems. Real-time data monitoring involves analyzing adverse event reports, social media, and health records to identify potential safety signals. Predictive analytics uses AI-driven models to forecast adverse drug reactions, enabling early intervention strategies. Active surveillance systems collect data from patient registries and insurance claims databases for early detection of safety signals.

6.2 Risk-Based Approach

Best practices for drug management include risk prioritization, continuous benefit-risk assessment, and adaptive safety monitoring. Risk prioritization involves focusing resources on identifying and managing significant risks associated with a drug, while benefit-risk assessment evaluates a drug's benefits against risks throughout its lifecycle. Adaptive safety monitoring ensures responsiveness to new information and evolving risk profiles.

6.3 Collaboration and Communication

The best practices for enhancing pharmacovigilance include fostering collaboration among regulatory agencies, healthcare professionals, patients, and the pharmaceutical industry, establishing transparent information sharing channels, and promoting global harmonization to standardize practices and risk communication strategies across different regions, thereby ensuring consistency and reliability in drug safety monitoring.

6.4 Continuous Monitoring and Evaluation

Regular safety audits are essential for ensuring compliance with regulatory standards in pharmacovigilance processes. Key performance indicators (KPIs) are developed and monitored to assess the effectiveness of these activities and implement corrective actions. Continuous feedback from stakeholders is crucial for refining risk management strategies and enhancing drug safety profiles over time.

II. CONCLUSION

Pharmacovigilance is a vital aspect of drug safety, ensuring that medications remain effective and minimize risks throughout their lifecycle. Clinical trials provide initial insights into safety and efficacy, but they cannot capture all possible adverse effects due to controlled conditions and limited sample sizes. Post-marketing surveillance is essential for detecting long-term and rare adverse reactions, making

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 2484-2490 www.ijprajournal.com ISSN: 2456-4494

pharmacovigilance indispensable in safeguarding public health. A robust pharmacovigilance system relies on collaboration among pharmaceutical companies, healthcare professionals, regulatory authorities, and patients. Regulatory frameworks set by organizations like the WHO, FDA, EMA, and ICH ensure standardized monitoring and reporting of adverse drug reactions (ADRs). Compliance with these guidelines enhances drug safety and maintains public confidence in medical treatments.

Technological advancements have significantly improved pharmacovigilance processes, with artificial intelligence (AI), data mining, and big data analytics enabling faster and more accurate detection of safety signals. Machine learning algorithms can analyze vast datasets, identifying patterns that indicate potential risks. Blockchain technology enhances data security, ensuring the integrity and transparency of safety reports. The integration of real-world data from electronic health records, patient registries, and social media strengthens ADR detection and risk assessment.

Despite challenges like regulatory inconsistencies and data integration complexities, the future of pharmacovigilance is promising. Strengthening international collaboration, standardizing reporting frameworks, and leveraging digital innovations will enhance drug safety monitoring. Continued investment in AI-driven tools and automated risk management systems will improve efficiency and response times to emerging safety concerns.

REFERENCE:

[1]. Doan, T., Renz, C., Lievano, F., Bhattacharya, M., &Scarazzini, L. (2018). Pharmacovigilance: A Practical Approach. Elsevier.
[2]. Mann, R. D., & Andrews, E. B. (Eds.). (2007). Pharmacovigilance (2nd ed.). John Wiley & Sons.
[3]. Waller, P. (2017). An Introduction to Pharmacovigilance (2nd ed.). Wiley-Blackwell.
[4]. Dinkel, R., Lindquist, M., Knezevic, I., & Edwards, R. (Eds.). (2017). Pharmacovigilance: Critique and Ways Forward. Springer.
[5]. Klepper, M. J. (2024). Principles and Practice of Pharmacovigilance and Drug Safety. Springer.
[6]. Cobert, B. L., & Biron, P. (2009). Manual of Drug Safety and Pharmacovigilance. Jones & Bartlett Learning.
[7]. Talbot, J. C., & Waller, P. C. (2004). Stephens' Detection of New Adverse Drug Reactions. John Wiley & Sons.
[8]. Gupta, S. K. (2011). Drug Safety and Pharmacovigilance. Jaypee Brothers Medical Publishers.
[9]. Aronson, J. K. (2016). Side Effects of Drugs Annual: A Worldwide Yearly Survey of New Data and Trends in Adverse Drug Reactions. Elsevier.
[10]. European Medicines Agency (EMA). (2017). Guideline on Strategies to Identify and Mitigate Risks for First-In-Human and Early Clinical Trials with Investigational Medicinal Products.
[11]. Rawlins, M. D. (2011). Drug Safety: Science, Politics, and the Public. Cambridge University Press.
[12]. Edwards, I. R., & Aronson, J. K. (2000). Adverse drug reactions: definitions, diagnosis, and management. The Lancet, 356(9237), 1255-1259.
[13]. Rawlins, M. D., & Thompson, J. W. (1991). Mechanisms of adverse drug reactions. In Davies, D. M. (Ed.), Textbook of Adverse Drug Reactions (4th ed., pp. 18-45). Oxford University Press.
[14]. Strom, B. L., Kimmel, S. E., & Hennessy, S. (2019). Pharmacoepidemiology (6th ed.). John Wiley & Sons.
[15]. Sarah J. Rondeau. The Pharma Review Nov- Dec 2011KONGPOSH Publications Pvt. Ltd. ICS House, C19, Commercial Complex, SDA, Opp. IIT Gate, New Delhi, India -110016
[16]. Muhannad RMS, et al. Physicians' knowledge about pharmacovigilance in Iraq. J Pharmacovigilance. 2016;4:214.
[17]. Hama R. The Mechanisms of Adverse Reactions to Oseltamivir: Part II. Delayed Type Reactions. ClinMicrobiol. 2015;4:224.
[18]. Klepper MJ. The periodic safety update report as a pharmacovigilance tool. Drug Safety. 2004;27:569- 578.
[19]. Kowalski CJ and Mrdjenovich AJ. Pharmacovigilance Observed: Why Watchful Waiting will Work. J ClinDiagn Res. 2015;3:114.
[20]. Finch, E. (2024). Enhancing Drug Safety through Proactive Pharmacovigilance

Strategies and Innovations. Journal of Pharmacovigilance, 12(3).

[21]. Nord, M., Ysander, M., Sullivan, T., & Patel, M. (2021). Practical considerations for creating a strategic and proactive clinical safety and pharmacovigilance organization for the future. International Journal of Risk & Safety in Medicine, 32(3), 243–258.

[22]. Nord, M., Ysander, M., Sullivan, T., & Patel, M. (2021). Practical considerations for creating a strategic and proactive clinical safety and pharmacovigilance organization for the future. International Journal of Risk & Safety in Medicine, 32(3), 243–258.

[23]. Nelson, R.C., Palsulich, B., & Gogolak, V. (2002). Good Pharmacovigilance Practices. Drug Safety, 25(6), 407–414.

[24]. Pietrek, M., Coulson, R., & Czarnecki, A. (2009). Good Pharmacovigilance Practice: The Way Forward? Therapeutic Innovation & Regulatory Science, 43(5), 623–632.

[25]. Kugener, V.F., Freedland, E.S., Maynard, K.I., Aimer, O., Webster, P.S., Salas, M., & Gossell-Williams, M. (2021). Enhancing Pharmacovigilance from the US Experience: Current Practices and Future Opportunities. Drug Safety, 44(8), 843–852.

[26]. Bhati, N., Kannan, S., & Khosla, P.P. (2015). Good Pharmacovigilance Practice: Need of the Hour from Pharmaceutical Companies. Perspectives in Clinical Research, 6(3), 171–172.

[27]. Dol, H.S., Shinde, V.R., Mali, J.V., &Khakal, N.N. (2017). Pharmacovigilance: A Practical Approach for Reshaping Patient Safety. Innovare Journal of Medical Sciences, 5(2), 1–4.

[28]. Kumar, S., Sharma, A., & Gupta, B. (2023). A Critical Review of Drug Safety and Pharmacovigilance Practices. Acta Pharma Reports, 2(2). https://doi.org/10.51470/APR.2023.2.2.05

[29]. Gupta, D. K., Tiwari, A., Yadav, Y., Soni, P., & Joshi, M. (2024). Ensuring Safety and Efficacy in Combination Products: Regulatory Challenges and Best Practices. Frontiers in Medical Technology, 6. https://doi.org/10.3389/fmedt.2024.1377443

[30]. Vivekanandan, K., Rishi, K., Prasad, T., Arunabh, T., & Singh, G. N. (2015). Status of Documentation Grading and Completeness Score for Indian Individual Case Safety Reports. Indian Journal of Pharmacology, 47(3), 325–327.

[31]. Rehan HS, et al. Physicians guide to pharmacovigilance:terminology and causality assessment. Eur J Intern Med., 2009; 20: 3-8.

[32]. Sanaa A, et al. Awareness and Perception of National Pharmacovigilance centeramongLebanese Medical Staff. J Pharmacovigilance, 2016; 4: 199.